Wuxi Biologics (Cayman) Stock Sheds 2.5% in Hong Kong

Dow Jones16:32

Two Sessions Set New Course! Analysts Favor These Sectors as Fund Managers Map Out '2026 Investment Blueprint'

During the Two Sessions in 2026, the draft outline of the '15th Five-Year Plan' and the government work report not only provided a clear blueprint for economic development and policy direction but also signaled numerous investment opportunities.

Securities Times China08:54

Wuxi Issuing 40M Overallotment H-Shrs at HK$45.80 Each

Dow Jones08:30

Express News | Zheng Shanjie: The output value related to the six major emerging pillar industries—integrated circuits, aerospace, biomedicine, and others—is expected to exceed 10 trillion yuan by 2030.

BreakingsMar 6 16:46

Hong Kong-listed innovative pharmaceutical companies are leveraging policy support. Institutions: The biopharmaceutical sector is transitioning from an 'R&D investment phase' to a 'value harvest phase.'

① Why has the biopharmaceutical sector recently attracted significant market attention? ② How do institutions view recent policies?

cls.cnMar 6 14:05

Surging BD transactions and policy catalysts! The Hang Seng Medicine ETF (159892) surged by 3.67%, while the HK Connect Healthcare ETF (520510) rose by 2.89%, with its real-time turnover rate ranking first among similar products.

Gelonghui, March 6th | Today, the innovative drug sector rebounded strongly. The constituent stock 3SBio Inc. surged by 10%, driving the Hang Seng Medicine ETF (159892) to rise by 3.67%. The Stock Connect Healthcare ETF (520510) increased by 2.89%, with a turnover rate of 54.58%, ranking first among similar products. In terms of news: ① The 2026 Government Work Report identifies new quality productive forces as a core focus, listing biomedicine alongside integrated circuits, aerospace, and low-altitude economy for the first time, clearly defining it as a national 'emerging pillar industry.' It is expected that innovative drugs will receive more concentrated policy support, funding, and resource allocation. ② Business development (BD) transactions continue.

Gelonghui FinanceMar 6 13:01